CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
42.64 EUR
+0.3 (+0.71%)
Overall AFX gets a fundamental rating of 5 out of 10. We evaluated AFX against 65 industry peers in the Health Care Equipment & Supplies industry. AFX has an average financial health and profitability rating. AFX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
AFX had positive earnings in the past year.
In the past year AFX had a positive cash flow from operations.
Each year in the past 5 years AFX has been profitable.
AFX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AFX (4.15%) is comparable to the rest of the industry.
AFX's Return On Equity of 6.67% is in line compared to the rest of the industry. AFX outperforms 50.77% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.79%, AFX is in line with its industry, outperforming 52.31% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for AFX is below the industry average of 10.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
The Profit Margin of AFX (6.34%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of AFX has declined.
AFX has a Operating Margin (10.03%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of AFX has declined.
AFX has a worse Gross Margin (52.76%) than 60.00% of its industry peers.
In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AFX is creating some value.
Compared to 1 year ago, AFX has about the same amount of shares outstanding.
The number of shares outstanding for AFX has been reduced compared to 5 years ago.
The debt/assets ratio for AFX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.54 indicates that AFX is not in any danger for bankruptcy at the moment.
AFX's Altman-Z score of 3.54 is fine compared to the rest of the industry. AFX outperforms 64.62% of its industry peers.
AFX has a debt to FCF ratio of 4.41. This is a neutral value as AFX would need 4.41 years to pay back of all of its debts.
AFX has a Debt to FCF ratio of 4.41. This is comparable to the rest of the industry: AFX outperforms 53.85% of its industry peers.
AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
AFX's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. AFX outperforms 58.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 3.54 |
ROIC/WACC0.86
WACC6.75%
2.3 Liquidity
A Current Ratio of 2.35 indicates that AFX has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.35, AFX is doing good in the industry, outperforming 69.23% of the companies in the same industry.
AFX has a Quick Ratio of 1.44. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.44, AFX is doing good in the industry, outperforming 72.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.90%.
AFX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
The Revenue has been growing slightly by 7.82% in the past year.
AFX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.78% yearly.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
3.2 Future
Based on estimates for the next years, AFX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.13% on average per year.
AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.98% yearly.
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y20.13%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.98%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.48, which means the current valuation is very expensive for AFX.
Based on the Price/Earnings ratio, AFX is valued a bit cheaper than the industry average as 67.69% of the companies are valued more expensively.
AFX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.17, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 21.28 indicates a rather expensive valuation of AFX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 63.08% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.79, AFX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.48 | ||
| Fwd PE | 21.28 |
4.2 Price Multiples
AFX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AFX is cheaper than 78.46% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AFX is valued a bit cheaper than the industry average as 69.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.62 | ||
| EV/EBITDA | 12.29 |
4.3 Compensation for Growth
AFX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AFX's earnings are expected to grow with 22.65% in the coming years.
PEG (NY)1.08
PEG (5Y)8.07
EPS Next 2Y22.06%
EPS Next 3Y22.65%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.38%, AFX has a reasonable but not impressive dividend return.
AFX's Dividend Yield is a higher than the industry average which is at 0.98.
AFX's Dividend Yield is slightly below the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
5.2 History
The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
AFX pays out 37.19% of its income as dividend. This is a sustainable payout ratio.
DP37.19%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
FRA:AFX (1/7/2026, 5:36:15 PM)
42.64
+0.3 (+0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.81B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts73.64
Price Target51.15 (19.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.94%
PT rev (3m)-7.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.58%
EPS NY rev (3m)-6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.64%
Revenue NY rev (3m)-0.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.48 | ||
| Fwd PE | 21.28 | ||
| P/S | 1.71 | ||
| P/FCF | 28.62 | ||
| P/OCF | 18.17 | ||
| P/B | 1.8 | ||
| P/tB | 7.88 | ||
| EV/EBITDA | 12.29 |
EPS(TTM)1.61
EY3.78%
EPS(NY)2
Fwd EY4.7%
FCF(TTM)1.49
FCFY3.49%
OCF(TTM)2.35
OCFY5.5%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)1.08
PEG (5Y)8.07
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 3.54 |
F-Score6
WACC6.75%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y20.13%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.98%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year66.85%
EBIT Next 3Y28.21%
EBIT Next 5Y23.57%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 26.48 and the Price/Book (PB) ratio is 1.8.
Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?
The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 3 / 10 and the dividend payout ratio is 37.19%.